Xiang Wang

Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis.

Yangang Wang, Liyan Shen, Yue Zhou, 2019, The Journal of clinical endocrinology and metabolism.

Meta‐analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add‐on to metformin in type 2 diabetes

Yangang Wang, Liyan Shen, Yue Zhou, 2020, Diabetes/Metabolism Research and Reviews.

C‐peptide, glycaemic control, and diabetic complications in type 2 diabetes mellitus: A real‐world study

Yangang Wang, Yue Zhou, Yajing Huang, 2021, Diabetes/metabolism research and reviews.

LncRNA ZFAS1 regulates the proliferation, oxidative stress, fibrosis, and inflammation of high glucose-induced human mesangial cells via the miR-588/ROCK1 axis

Yangang Wang, Zhongchao Wang, B. Dong, 2022, Diabetology & Metabolic Syndrome.

MiR‐223‐3p and miR‐22‐3p inhibit monosodium urate‐induced gouty inflammation by targeting NLRP3

Yangang Wang, Ying Chen, B. Dong, 2021, International journal of rheumatic diseases.

LncRNA NNT-AS1 regulates proliferation, ECM accumulation and inflammation of human mesangial cells induced by high glucose through miR-214-5p/smad4

Yangang Wang, B. Dong, Lili Xu, 2021, BMC Nephrology.

The renoprotective effects of sodium‐glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta‐analysis

Yangang Wang, W. Lv, Yue Zhou, 2019, Diabetes, obesity & metabolism.

Meta‐analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add‐on to metformin in type 2 diabetes

Yangang Wang, Liyan Shen, Yue Zhou, 2019, Diabetes/metabolism research and reviews.